Treatment of Pituitary Gigantism in Germline AIP Gene Mutation
Germline mutations in the AIP gene represent the primary known genetic cause of pituitary gigantism. Managing this subgroup requires a targeted approach, as AIP-mutated tumors carry a high growth hormone secretory potential and may respond poorly to standard hormonal therapies.
Clinical Scenario
This protocol applies to patients with a confirmed germline AIP gene mutation. AIP mutations account for approximately 29% of pituitary gigantism cases, making this the most commonly identified genetic subtype. The high secretory burden and potential for reduced sensitivity to first-line agents define the clinical challenge.
Treatment Goals
- Control of IGF-1 excess
- Decreased height gain
Treatment Approach — Partial Overview
When somatostatin analog therapy alone proves insufficient in AIP-mutated pituitary gigantism, the protocol includes a GH receptor antagonist-based strategy. This approach can be employed as monotherapy or in combination with other agents, including in pediatric patients with intolerance or resistance. Surgical options also feature in the protocol under specific conditions.
The complete protocol — covering the full sequence of options, specific agents, combination strategies, and surgical criteria — is available via the link below.
References
DOI: 10.1016/B978-0-12-814537-1.00002-6
- Germline mutations in the AIP gene are the main known cause of pituitary gigantism.
- Among pituitary gigantism patients themselves, 29% have an AIP mutation.
- Resistance to first-generation somatostatin analogs like octreotide and lanreotide can be countered by use of the GH receptor antagonist, pegvisomant, in the setting of acromegaly and gigantism with or without AIP mutations.
- Treatment with pegvisomant can take the form of monotherapy or it can be used in combination with somatostatin analogs.
- Either alone or in combination with somatostatin analogs, pegvisomant is an important and useful option for controlling IGF-1 excess and decreasing height gain in AIP-mutated pituitary gigantism cases that are resistant to somatostatin analogs alone.
View source ↗